SCHEDULE 13G/A: Punch & Associates Investment Management Discloses 0.1% Stake in Harvard Bioscience

Punch & Associates Investment Management, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 0.1% of Harvard Bioscience Inc.'s common stock as of March 31, 2025.

Summary

• Punch & Associates Investment Management, Inc. filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in Harvard Bioscience Inc.
• The filing indicates that Punch & Associates Investment Management, Inc. beneficially owns 25,586 shares of Harvard Bioscience Inc. common stock.
• This ownership represents 0.1% of the class of securities.
• The reporting person, Punch & Associates Investment Management, Inc., has sole voting power and sole dispositive power over all 25,586 shares.
• The filing was made pursuant to Rule 13d-1(b) and identifies Punch & Associates as an investment adviser.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing beneficial ownership, which is purely factual and does not convey positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment adviser, indicating a passive investment in Harvard Bioscience Inc. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a minor ownership stake by an investment firm, which is a standard disclosure and unlikely to have significant direct impact.

Key Dates

Keywords

Harvard Bioscience Inc., Punch & Associates Investment Management Inc., Schedule 13G, Common Stock, Beneficial Ownership, Investment Adviser, SEC Filing